Is Xylem (XYL) Undervalued After Q2 Earnings And A 2026 Guidance Cut?

Xylem (XYL) is back in focus after releasing second quarter 2026 results and trimming its full year 2026 revenue outlook, a combination that can change how investors weigh the stock’s risk and reward.

See our latest analysis for Xylem.

The recent guidance trim and second quarter update come after a patchy period for Xylem, with the share price at US$122.25 and the year-to-date share price return down 10.84%, even as the 3-year total shareholder return of 23.93% points to a stronger longer-run record than the more recent 1-year total shareholder return decline of 13.78%.

If the mix of buybacks, acquisitions and earnings has you thinking about where else capital intensive stories could go next, it may be worth scanning 36 power grid technology and infrastructure stocks

The question now is whether Xylem’s recent share price weakness and guidance trim reflect a change in the underlying business, or if sentiment has simply swung too far. The answer sits in the valuation.

Most Popular Narrative: 18.9% Undervalued

Against Xylem’s last close at $122.25, the most widely followed narrative points to a fair value of $150.65, which implies a sizeable valuation gap that rests on specific growth, margin and capital allocation assumptions.

Significant and increasing investment in aging water infrastructure (notably in the U.S. and U.K.) underpins a strong multi-year backlog (> $5 billion), with anticipated order rebounds as funding cycles and regulatory timelines normalize, supporting steady revenue growth and greater earnings visibility.

Read the complete narrative.

Want to see what is baked into that backlog story. The narrative leans heavily on steady revenue compounding, higher profitability and a richer earnings multiple. The exact mix of those inputs is what drives the $150.65 fair value, and it is not as straightforward as simple revenue growth.

Result: Fair Value of $150.65 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, Xylem’s story can change quickly if government infrastructure funding is delayed, or if integration risks around Evoqua and other acquisitions start to bite.

Find out about the key risks to this Xylem narrative.

Another View on Xylem’s Valuation

The first narrative leans on cash flow and backlog to argue that Xylem is undervalued. On a simple earnings multiple, the picture looks less generous. The stock trades on a P/E of 28x, compared with a peer average of 25.2x and a fair ratio of 27.3x.

That gap suggests investors are already paying a premium compared with both peers and the fair ratio the market could move toward. This reduces the margin for error if growth or margins fall short. The key question is whether you are comfortable paying above those markers given Xylem’s profile.

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

If this mix of caution and optimism on Xylem has you thinking hard about the balance of risks and rewards, take a moment to review the numbers directly and form your own stance. To see what optimistic investors are focusing on right now, start with 5 key rewards

Looking for more investment ideas beyond Xylem?

If you want to keep sharpening your edge after looking at Xylem, do not stop here. Fresh ideas can help you stress test your thinking and avoid tunnel vision.

• Spot potential value opportunities early by reviewing companies that screen well on quality and price through the 52 high quality undervalued stocks.
• Strengthen your focus on capital preservation by checking stocks that rank highly on resilience using the 79 resilient stocks with low risk scores.
• Broaden your watchlist with underfollowed businesses that still show solid fundamentals by scanning the screener containing 18 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com